Radiation therapy remains the key cost driver of oncology inpatient treatment

Journal of Medical Economics

Volumn 18, Issue 1, 2015, Pages 29-36

  Jakovljevic, Mihajlo ^a   Zugic, Ana ^a   Rankovic, Ana ^b   Dagovic, Aleksandar ^b  

^a University of Kragujevac Medical Faculty   (Serbia)

^b CLINICAL CENTRE KRAGUJEVAC   (Serbia)

Author keywords

Cancer; Costs; Hospital; Inpatient; Malignant tumor; Radiation therapy; Serbia; Treatment

Indexed keywords

ADULT; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; NURSING CARE; ONCOLOGY; SAMPLE SIZE; TELERADIOTHERAPY; UNIVERSITY HOSPITAL; AGED; ECONOMICS; HOSPITAL ADMISSION; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDY; SERBIA; STATISTICS AND NUMERICAL DATA; TELEMEDICINE;

AGED; BRACHYTHERAPY; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SERBIA; TELEMEDICINE; WAITING LISTS;

EID: 84918812472     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.971162     Document Type: Article

References (28)

1. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002;94:2766-92
2. Marta GN, Del Nero LG, Marta GN, et al. Treatment priorities in oncology: do we want to live longer or better? Clinics 2014;69:509
3. Siddiqui F, Liu AK, Watkins-Bruner D, et al. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. J Clin Oncol 2014;32:2920-7
4. Hayman J, Weeks J, Mauch P. Economic analyses in health care: an introduction to the methodogy with an emphasis on radiation therapy. Int J Radiat Oncol Biol Physics 1996;35:827-41
5. International Atomic Energy Agency. DIRAC (DIrectory of RAdiotherapy Centres). http://www-naweb.iaea.org/nahu/dirac/query3.asp Accessed October 2014
6. World Bank. Report No: 81924-YF; second Serbia health project (P129539). January 30, 2014. pp. 20.
7. Jakovljević M, Ranković A, Rancić N, et al. Radiology services costs and utilization patterns estimates in Southeastern Europe - A retrospective analysis from Serbia. Value in Health Regional Issues 2013;2:218-25
8. Jakovljevic MB. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia. Health Econ Therap Pathways 2014;15:27-32
9. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013;14:153-9
10. Leopold C, Mantel-Teeuwisse AK, Vogler S, et al. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Policy 2014:92(9). In press
11. Jakovljević M, Jovanović M, Lazić Z, et al. Current efforts and proposals to reduce healthcare costs in Serbia. SJECR 2011;12:161-3
12. Jacobs VR, Thoedtmann J, Euler U, et al. Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care. Onkologie 2005;28:441-5
13. Ranković A, Rancić N, Jovanović M, et al. Impact of imaging diagnostics on the budget: are we spending too much? Vojnosanitetski Pregled 2013;70:709-11
14. Høilund-Carlsen PF, Gerke O, Vach W. Demonstrating the benefits of clinical nuclear imaging: is it time to add economic analysis? Eur J Nucl Med Mol Imag 2014;41:1720-2
15. Wilson GW, Jadlow JM. Competition, profit incentives, and technical efficiency in the provision of nuclear medicine services. Bell J Econ 1982;2: 472-82
16. Sleijfer S. "It's the Economy, Stupid": strategies for improved cost containment in cancer treatment. Clin Pharmacol Therap 2014;95:365-7
17. Anand P, Kunnumakara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceut Res 2008;25: 2097-116
18. Weissman JS, Stern R, Fielding SL, et al. Delayed access to health care: risk factors, reasons, and consequences. Ann Intern Med 1991;114:325-31
19. Euro Care - Survival of cancer patients in Europe. http://www.eurocare.it/. Last accessed 25 August 2014
20. WHO European Cancer Observatory. http://eco.iarc.fr/. Last accessed 15 September 2014
21. Radovanović A, Dagović A, Jakovljević M. Economics of cancer related medical care: worldwide estimates and available domestic evidence. Arch Oncol 2011;19:59-63
22. Chauvet B, Mazeron JJ, Mahe MA, et al. White paper of radiotherapy in France. Twelve objectives to improve one of the major cancer treatments- 2013. Paris, France: Societe Francaise de Radiotherapie Oncologique-SFRO, Centre Antoine Beclere, Centre Universitaire des Saints Peres, 2013
23. Jakovljevic M, Gutzwiller F, Schwenkglenks M, et al. Costs differentials among monoclonal antibodies-based first-line oncology treatment protocols for breast cancer, colorectal Carcinoma and non-Hodgkin's lymphoma. JBUON 2014; in press
24. Liljegren G, Karlsson G, Bergh J, et al. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann oncol 1997;8:757-63
25. Rutigliano MJ, Lunsford LD, Kondziolka D, et al. The cost effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of solitary metastatic brain tumors. Neurosurgery 1995;37:445-55
26. Barbieri M, Weatherly HLA, Ara R, et al. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Appl Health Econ Health Policy 2014;12:497-510
27. Blank JL, Hulst B. Optimal administrative scale for planning public services: a social cost model applied to Flemish hospital care. Int J Health Plan Manage 2014. DOI: 10.1002/hpm.2246
28. Lievens Y, Grau C. Health economics in radiation oncology: introducing the ESTRO HERO project. Radiother Oncol 2012;103:109-12